| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 7.4 | 6.9 |
| Gross profit | 3.4 | 3.0 |
| Profit before tax | -0.0 | -0.1 |
| Net income | -0.0 | -0.1 |
| EPS (diluted, $ a share) | — | $-0.05 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +7.3% |
|---|---|
| Gross margin | 45.7% |
| Operating margin | 0.0% |
10-Q filed with the SEC, NASDAQ: PRPO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Precipio, Inc.: key numbers
- Share price
- $19.96Close, Nov 16
- Market cap
- $35.8M
- Shares outstanding
- 1.79MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Precipio, Inc.
All →Precipio Financial Results
Precipio reported record quarterly revenue of $7.3 million for Q3 2026, driven by growth in both its pathology and product segments. The company achieved positive Adjusted EBITDA of $0.4 million and generated $0.6 million in cash flow from operations, ending the period with a cash balance of $3.5 million.
- Term
- Q3 2026
“In the third quarter we continued to strengthen our financial position, delivering record revenue while maintaining positive Adjusted EBITDA and generating cash from operations.”
Ilan Danieli, CEO of Precipio
“Our pathology business continues to provide a strong operational and financial foundation for growth, while also serving as the clinical development and validation platform for our proprietary diagnostic products.”
Ilan Danieli, CEO of Precipio